China Uniquely Suited To Build Pharma 3.0 From The Ground Up As Healthcare Reform Rolls Out
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - As the pharmaceutical industry begins to embrace new business models that utilize the newest advances in information technology to achieve better health outcomes, China may be uniquely suited to implement such a system from the ground up, Ernst & Young said during a life sciences roundtable discussion with local reporters in Shanghai March 25
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).